A clinical trial: Aqualizer ™ therapy and its effects on myopathies or temporomandibular dysfunctions. Part II: Subjective parameters.

Autor:	Buchbender M; Department of Oral and Maxillofacial Surgery, University of Erlangen- Nuremberg, Erlangen, Germany., Keplinger L; Department of Oral and Maxillofacial Surgery, University of Erlangen- Nuremberg, Erlangen, Germany., Kesting MR; Head of the Department of Oral and Maxillofacial Surgery, University of Erlangen- Nuremberg, Erlangen, Germany., Adler W; Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen Nuremberg, Erlangen, Germany., Schmitt CM; Department of Oral and Maxillofacial Surgery, University of Erlangen- Nuremberg, Erlangen, Germany.
Jazyk:	angličtina
Zdroj:	Cranio : the journal of craniomandibular practice [Cranio] 2023 Nov; Vol. 41 (6), pp. 479-485. Date of Electronic Publication: 2021 Feb 13.
DOI:	10.1080/08869634.2021.1885887
Abstrakt:	Objective: Temporomandibular dysfunction (TMD) reduces patients' quality of life (QoL). The aim was to assess the effects of initial Aqualizer™ therapy. Methods: Group 1 (initial Aqualizer™ therapy) before definitive splint therapy or Group 2 (no initial therapy). Patients with arthrosis, partial/total prosthesis, or were undergoing splint therapy were excluded. Subjective parameters were evaluated: duration and intensity of pain, influence on wellbeing, changes in the head/neck area, handling and improvement of the Aqualizer™, improvement in QoL. The statistical significance level was 5% (p < 0.05). Results: In 53 patients (Group 1 n = 25; Group 2 n = 28), the improvement in patients' well-being and intensity of pain in both groups was significant (p < 0.001). An improvement in QoL was found in 84% of patients in Group 1 and 75% in Group 2. Conclusion: Initial Aqualizer™ therapy can decrease the intensity of pain and increase patients'.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu